- Home
- GPCR
as 12-18-2024 11:37am EST
Stocks
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 1.8B | IPO Year: | 2023 |
| Target Price: | $85.67 | AVG Volume (30 days): | 797.2K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $29.48 - $62.74 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Structure Therapeutics Inc. News
GPCR Breaking Stock News: Dive into GPCR Ticker-Specific Updates for Smart Investing
GlobeNewswire
20 hours ago
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Insider Monkey
2 days ago
Is Structure Therapeutics Inc. (GPCR) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
TipRanks
10 days ago
Jefferies Predicts Up to ~1000% Surge for These 2 ‘Strong Buy’ Stocks
MT Newswires
14 days ago
HC Wainwright Initiates Structure Therapeutics at Buy
Insider Monkey
21 days ago
Why Is Structure Therapeutics Inc. (GPCR) Among the Best Up and Coming Stocks to Buy According to Analysts?
Insider Monkey
a month ago
Structure Therapeutics Inc. (GPCR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
GlobeNewswire
a month ago
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
GlobeNewswire
a month ago
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
Compare GPCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GPCR Structure Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.